Corporate Biotech Incubators

Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures

When Pfizer Inc. and Biogen Inc. set up their respective incubators in 2007, the idea was to identify—very early on—good ideas and to nurture them into young companies, showering them with the experience, knowledge and resources of the parent firm. For Biogen, the project was overtly strategic from the start: its purpose was to fuel the Big Biotech's early-stage pipeline, providing housing only in exchange for pre-negotiated option rights. Pfizer's project started with a loftier, more blue-sky outlook—pulling in cool science for the sake of it—but has since narrowed to something highly strategic, too.

These two companies are among the few corporates to dip their toes into incubating—in the traditional, physical sense of providing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.